A Deeper Dive Into Design Therapeutics
Lexeo Therapeutics Inc LXEO
$4.13
▼ -5.06%
($-0.22)
🧊 52W Low
⬇️ Below Yest. Low
🔥 High Short Interest
🗓️ Earnings Next Week
Open
$4.38
Prev Close
$4.35
Day Range
$4.07 – $4.38
52W Range
$4.03 – $10.99
Market Cap
$324.29M
Beta
1.45
EPS (TTM)
$-1.45
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2023-11-03 |
| Shares Out. | 78,520,000 |
| Website | lexeotx.com/ ↗ |
| Phone | 12125479879 |
| Employees | 59 |
| Net Income | -$20.2M |
| Free Cash Flow | -$98.4M |
| Total Assets | $250.4M |
| Total Liabilities | $18.9M |
| Equity | $231.5M |
About Lexeo Therapeutics Inc
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
Lexeo Therapeutics Inc is a publicly traded company under the ticker symbol LXEO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-07-01)